Discovery of a novel noniminosugar acid α glucosidase chaperone series

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7546-7559

  Xiao, Jingbo ^a   Westbroek, Wendy ^b   Motabar, Omid ^a   Lea, Wendy A ^a   Hu, Xin ^a   Velayati, Arash ^b   Zheng, Wei ^a   Southall, Noel ^a   Gustafson, Ann Marie ^b   Goldin, Ehud ^b   Sidransky, Ellen ^b   Liu, Ke ^a   Simeonov, Anton ^a   Tamargo, Rafael J ^b   Ribes, Antonia ^c   Matalonga, Leslie ^c   Ferrer, Marc ^a   Marugan, Juan J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL]PHENYL]PYRROLIDIN 2 ONE; 4 [4 (2 OXOINDOLIN 5 YL SULFONYL )PIPERAZIN 1 YL]BENZALDEHYDE; 4 [4 (2 OXOINDOLIN 5 YLSULFONYL)PIPERAZIN 1 YL]BENZOIC ACID; 4 [4 (2 OXOINDOLIN 5 YLSULFONYL)PIPERAZIN 1 YL]BENZONITRILE; 5 (4 4 TOLYLPIPERAZIN 1 YLSULFONYL)INDOLIN 2 ONE; 5 (4 ACETYLPIPERAZIN 1 YLSULFONYL)INDOLIN 2 ONE; 5 (PIPERAZIN 1 YLSULFONYL)INDOLIN 2 ONE; 5 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL) 1H BENZO[D]IMIDAZOL 2 (3H)ONE; 5 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL] 3,3 DICHLOROINDOLIN 2 ONE; 5 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL] 6 CHLOROINDOLIN 2 ONE; 5 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 5 [4 (4 BROMOPHENYL)PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 5 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 5 [4 (4 FLUOROPHENYL)PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 5 [4 (4 HYDROXYPHENYL)PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 5 [4 (4 METHOXYPHENYL)PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 5 [4 (4 NITROPHENYL)PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 5 [4 [3 (TRIFLUOROMETHYL)PHENYL]PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 5 [4 [4 (HYDROXYMETHYL)PHENYL]PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 5 [4 [4 (TRIFLUOROMETHYL)PHENYL]PIPERAZIN 1 YLSULFONYL]INDOLIN 2 ONE; 6 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YL SULFONYL) 3 METHYLBENZO[D]OXAZOL 2 (3H)ONE; 6 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL) 3,4 DIHYDROQUINOLIN 2 (1H)ONE; 6 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL]BENZO[D]OXAZOL 2 (3H)ONE; 6 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL]ISOBENZOFURAN 1 (3H)ONE; 7 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL) 4,5 DIHYDRO 1H BENZO[B]AZEPIN 2 (3H)ONE; ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE INHIBITOR; METHYL 4 [4 (2 OXOINDOLIN 5 YLSULFONYL)PIPERAZIN 1 YL]BENZOATE; N[4 [4 (4 ACETYLPHENYL)PIPERAZIN 1 YLSULFONYL]PHENYL]ACETAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; GLYCOGEN STORAGE DISEASE TYPE 2; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYSOSOME; MOUSE; NONHUMAN;

ALPHA-GLUCOSIDASES; BLOTTING, WESTERN; CELLS, CULTURED; DRUG DISCOVERY; ENZYME REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; IMINO SUGARS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, CONFOCAL; MOLECULAR CHAPERONES; SMALL MOLECULE LIBRARIES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866338441     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3005543     Document Type: Article

References (34)

1. Smid, B. E.; Aerts, J. M. F. G.; Boot, R. G.; Linthorst, G. E.; Hollak, C. E. M. Pharmacological small molecules for the treatment of lysosomal storage disorders Expert Opin. Invest. Drugs 2010, 19, 1367-1379
2. Hirschhorn, R.; Reuser, A. J. J. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In The Metabolic and Molecular Bases of Inherited Disease; Valle, D., Ed.; McGraw-Hill: New York, 2001, Chapter 135.
3. Martiniuk, F.; Chen, A.; Mack, A.; Arvanitopoulos, E.; Chen, Y.; Rom, W. N.; Codd, W. J.; Hanna, B.; Alcabes, P.; Raben, N.; Plotz, P. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease Am. J. Med. Genet. 1998, 79, 69-72 (Pubitemid 28402423)
4. The Human Gene Mutation Database; Institute of Medical Genetics: Cardiff; http://www.hgmd.cf.ac.uk
5. Raben, N.; Plotz, P.; Byrne, B. J. Acid α-glucosidase deficiency (glycogenosis type II, Pompe disease) Curr. Mol. Med. 2002, 2, 145-166 (Pubitemid 34649837)
6. Myozyme: Treatment for Pompe Disease; Genzyme: Cambridge, MA; http://www.myozyme.com/
7. Kishnani, P. S.; Corzo, D.; Nicolino, M.; Byrne, B.; Mandel, H.; Hwu, W. L.; Leslie, N.; Levine, J.; Spencer, C.; McDonald, M.; Li, J.; Dumontier, J.; Halberthal, M.; Chien, Y. H.; Hopkin, R.; Vijayaraghavan, S.; Gruskin, D.; Bartholomew, D.; van der Ploeg, A.; Clancy, J. P.; Parini, R.; Morin, G.; Beck, M.; De la Gastine, G. S.; Jokic, M.; Thurberg, B.; Richards, S.; Bali, D.; Davison, M.; Worden, M. A.; Chen, Y. T.; Wraith, J. E. Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease Neurology 2007, 68, 99-109 (Pubitemid 46071892)
8. Myozyme; RxList Inc.: New York; http://www.rxlist.com/myozyme-drug.htm.
9. Alglucosidase alfa; http://en.wikipedia.org/wiki/Myozyme.
10. Fan, J.-Q.; Ishii, S. Active-site-specific chaperone therapy for Fabry disease: Yin and Yang of enzyme inhibitors FEBS J. 2007, 274, 4962-4971 (Pubitemid 47481192)
11. Hermans, M. M. P.; van Leenen, D.; Kroos, M. A.; Beesley, C. E.; van der Ploeg, A. T.; Sakuraba, H.; Wevers, R.; Kleijer, W.; Michelakakis, H.; Kirk, E. P.; Fletcher, J.; Bosshard, N.; Basel-Vanagaite, L.; Besley, G.; Reuser, A. J. J. Twenty-two novel mutations in the lysosomal α-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II Hum. Mutat. 2004, 23, 47-56 (Pubitemid 38056101)
12. Montalvo, A. L. E.; Cariati, R.; Deganuto, M.; Guerci, V.; Garcia, R.; Ciana, G.; Bembi, B.; Pittis, M. G. Glycogenosis type II: identification and expression of three novel mutations in the acid α-glucosidase gene causing the infantile form of the disease Mol. Genet. Metab. 2004, 81, 203-208 (Pubitemid 38221451)
13. Reuser, A. J. J.; Kroos, M.; Oude, E. R. P. J.; Tager, J. M. Defects in synthesis, phosphorylation, and maturation of acid α-glucosidase in glycogenosis type II J. Biol. Chem. 1985, 260, 8336-8341 (Pubitemid 15249838)
14. Reuser, A. J. J.; Kroos, M.; Willemsen, R.; Swallow, D.; Tager, J. M.; Galjaard, H. Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid α-glucosidase in mutant fibroblasts J. Clin. Invest. 1987, 79, 1689-1699 (Pubitemid 17117275)
15. Beck, M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy Hum. Genet. 2007, 121, 1-22 (Pubitemid 46421136)
16. Asano, N. Glycosidase inhibitors: update and perspectives on practical use Glycobiology 2003, 13, 93R-104R (Pubitemid 37337046)
17. Yoshimizu, M.; Tajima, Y.; Matsuzawa, F.; Aikawa, S.-i.; Iwamoto, K.; Kobayashi, T.; Edmunds, T.; Fujishima, K.; Tsuji, D.; Itoh, K.; Ikekita, M.; Kawashima, I.; Sugawara, K.; Ohyanagi, N.; Suzuki, T.; Togawa, T.; Ohno, K.; Sakuraba, H. Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid [alpha]-glucosidase (alglucosidase alfa): Insight into the complex formation mechanism Clin. Chim. Acta 2008, 391, 68-73
18. Fan, J.-Q. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity Biol. Chem. 2008, 389, 1-11 (Pubitemid 350308199)
19. Alpha-glucosidase inhibitor; http://en.wikipedia.org/wiki/Alpha- glucosidase-inhibitor.
20. Butters, T. D.; Dwek, R. A.; Platt, F. M. Therapeutic applications of imino sugars in lysosomal storage disorders Curr. Top. Med. Chem. 2003, 3, 561-574
21. Lieberman, R. L.; D'aquino, J. A.; Ringe, D.; Petsko, G. A. Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and Stability Biochemistry 2009, 48, 4816-4827
22. Flanagan, J. J.; Rossi, B.; Tang, K.; Wu, X.; Mascioli, K.; Donaudy, F.; Tuzzi, M. R.; Fontana, F.; Cubellis, M. V.; Porto, C.; Benjamin, E.; Lockhart, D. J.; Valenzano, K. J.; Andria, G.; Parenti, G.; Do, H. V. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase Hum. Mutat. 2009, 30, 1683-1692
23. Okumiya, T.; Kroos, M. A.; Van Vliet, L.; Takeuchi, H.; Van der Ploeg, A. T.; Reuser, A. J. J. Chemical chaperones improve transport and enhance stability of mutant α-glucosidases in glycogen storage disease type II Mol. Genet. Metab. 2007, 90, 49-57 (Pubitemid 44856297)
24. Parenti, G.; Zuppaldi, A.; Pittis, M. G.; Tuzzi, M. R.; Annunziata, I.; Meroni, G.; Porto, C.; Donaudy, F.; Rossi, B.; Rossi, M.; Filocamo, M.; Donati, A.; Bembi, B.; Ballabio, A.; Andria, G. Pharmacological Enhancement of Mutated α-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease Mol. Ther. 2007, 15, 508-514
25. Motabar, O.; Shi, Z.-D.; Goldin, E.; Liu, K.; Southall, N.; Sidransky, E.; Austin, C. P.; Griffiths, G. L.; Zheng, W. A new resorufin-based α-glucosidase assay for high-throughput screening Anal. Biochem. 2009, 390, 79-84
26. John, M.; Wendeler, M.; Heller, M.; Sandhoff, K.; Kessler, H. Characterization of Human Saposins by NMR Spectroscopy Biochemistry 2006, 45, 5206-5216
27. Zwerschke, W.; Mannhardt, B.; Massimi, P.; Nauenburg, S.; Pim, D.; Nickel, W.; Banks, L.; Reuser, A. J.; Jansen-Durr, P. Allosteric activation of acid α-glucosidase by the human papillomavirus E7 protein J. Biol. Chem. 2000, 275, 9534-9541 (Pubitemid 30185183)
28. Marugan, J. J.; Zheng, W.; Motabar, O.; Southall, N.; Goldin, E.; Westbroek, W.; Stubblefield, B. K.; Sidransky, E.; Aungst, R. A.; Lea, W. A.; Simeonov, A.; Leister, W.; Austin, C. P. Evaluation of Quinazoline Analogues as Glucocerebrosidase Inhibitors with Chaperone Activity J. Med. Chem. 2011, 54, 1033-1058
29. Austin, C. P.; Brady, L. S.; Insel, T. R.; Collins, F. S. NIH Molecular Libraries Initiative Science 2004, 306, 1138-1139 (Pubitemid 39488980)
30. Inglese, J.; Auld, D. S.; Jadhav, A.; Johnson, R. L.; Simeonov, A.; Yasgar, A.; Zheng, W.; Austin, C. P. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11473-11478 (Pubitemid 44182476)
31. Bouchikhi, F.; Anizon, F.; Moreau, P. Synthesis and antiproliferative activities of isoindigo and azaisoindigo derivatives Eur. J. Med. Chem. 2008, 43, 755-762 (Pubitemid 351446148)
32. Vedadi, M.; Niesen, F. H.; Allali-Hassani, A.; Fedorov, O. Y.; Finerty, P. J.; Wasney, G. A.; Yeung, R.; Arrowsmith, C.; Ball, L. J.; Berglund, H.; Hui, R.; Marsden, B. D.; Nordlund, P.; Sundstrom, M.; Weigelt, J.; Edwards, A. M. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 15835-15840 (Pubitemid 44657553)
33. Jerabek-Willemsen, M.; Wienken, C. J.; Braun, D.; Baaske, P.; Duhr, S. Molecular interaction studies using microscale thermophoresis Assay Drug Dev. Technol. 2011, 9, 342-353
34. Niesen, F. H.; Berglund, H.; Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability Nature Protoc. 2007, 2, 2212-2221 (Pubitemid 351565860)